Drug Profile
Research programme: bacterial infections therapeutics - Vernalis
Alternative Names: BB 83815; BB 83857; BB 84234; BB 84416; BB 84518; BB 84887; BB 84888; BB 85035Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Class
- Mechanism of Action Metalloprotease inhibitors; Peptide deformylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anthrax; Community-acquired pneumonia; Gram-positive infections
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 14 Jan 2005 Discontinued - Preclinical for Anthrax in United Kingdom (unspecified route)
- 14 Jan 2005 Discontinued - Preclinical for Community-acquired pneumonia in United Kingdom (IV)